Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MFIC 1.73 - What I liked best in the Taglich report about MFIC were the comments that "the advent of MRT could potentilly unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. Bruno (MFIC's President) further stated that MRT provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader. The Company anticipateds introducing a line of equipment to facilitate the MRT process in the fourth quarter of fiscal 2007."
If MFIC's new MRT disruptive technology will garner orders from Big Pharma/Biotech and other industries there is no telling high the stock can go. This stock has a tiny market cap of only $17 Million and a very thin float. Even Taglich Brothers indicated that they will have to revisit their sales and earnings estimates once this product with an estimated price tag of $400K to $500K starts to be shipped in Q4/07.
New Taglich Bros. Research Report maintaining MFIC at Speculative Buy Rating:
http://www.taglichbrothers.com/equityuniverse/companies/mficcorp/mficcorp-06042007.pdf
Interesting. Thanks for posting that.
Harvard licenses more than 50 patents to nanotech start-up
A deal could transform the little-known Nano-Terra into one of nanotechnology's most closely watched start-ups.
By Barnaby J. Feder
The New York Times
Published: June 4, 2007, 6:06 AM PDT
George M. Whitesides, a Harvard University chemist, is a renowned specialist in nanotechnology, a field built on the behavior of materials as small as one molecule thick.
But there is nothing tiny about the patent portfolio that Harvard has amassed over the last 25 years based on work in his lab.
On Monday, Harvard and Nano-Terra, a company co-founded by Whitesides, plan to announce the exclusive licensing for more than 50 current and pending Harvard patents to Nano-Terra. The deal could transform the little-known Nano-Terra into one of nanotechnology's most closely watched start-ups.
"It's the largest patent portfolio I remember, and it may be our largest ever," said Isaac T. Kohlberg, who has overseen the commercialization of Harvard's patent portfolio since 2005. Nano-Terra, based in Cambridge, Mass., said the patent filing and maintenance costs alone top $2 million.
Terms of the deal were not disclosed, but Harvard said it would receive a significant equity stake in Nano-Terra in addition to royalties.
The patents cover methods of manipulating matter at the nanometer and micron scales to create novel surfaces and combinations of materials.
A nanometer is a billionth of a meter (proteins and the smallest elements in many microprocessor designs are measured in nanometers); a micron is 1,000 times larger (pollen and many single-cell animals are measured in microns). Such technology could lead to products to make better paints and windows, safer and cleaner chemicals, and more efficient solar panels.
The patents cover virtually all nonbiological applications of work performed by professor Whitesides and dozens of doctoral students over the last decade. The biology related research--mostly in health care--had previously been licensed to other companies involving Professor Whitesides, including Genzyme, GelTex (sold to Genzyme for $1.2 billion in 1993), Theravance and two privately held start-ups, Surface Logix and WMR Biomedical.
Nano-Terra, though, is selling no products. It is just offering manufacturing and design skills in realms where flexibility and low costs are crucial.
The best-known patents cover soft lithography, Whitesides' method of depositing extremely thin layers of material onto a surface in carefully controlled patterns. It can work over larger surfaces than photolithography, which is widely used to make microchips. Perhaps even more intriguing, soft lithography can work on highly irregular or rounded surfaces where photolithography is all but impossible.
But while nanotechnology's promise remains immense--the potential advances in energy, medicine and information technology have attracted billions of dollars in government and private investment in recent years--it is not yet clear which patents will prove valuable.
"You can't just go to market with a huge patent portfolio and a promising pipeline but no revenues," said Stephen B. Maebius, a patent lawyer in Washington and a nanotechnology expert. "That was the lesson of Nanosys," he said, referring to the aborted 2004 public offering of a company based in Palo Alto, Calif., that was the highest-profile nanotechnology start-up backed by venture capital.
Now on News.com
Mark your calendars: iPhone on June 29
Newsmaker: The copyright buzz from the 'Electric Slide'
China's new weapon: Low executive pay
Extra: McCain would hire Steve Ballmer
Nano-Terra was founded in 2005 with the goal of creating a home for the Whitesides patents. Its management team includes the vice chairman, Carmichael Rogers, a former student of Whitesides and a partner with him in two other companies; the chief executive, Myer Berlow, a former Time Warner marketing executive; and the president, Ueli Morant, a former market executive at IBM and Royal Philips Electronics.
Nano-Terra is part of a growing segment of nanotechnology start-ups. Other prominent academic researchers who have started nanotech companies include Chad A. Mirkin of Northwestern University (Nanosphere and NanoInk) and the late Richard E. Smalley of Rice University (Carbon Nanotechnologies).
Other leading Harvard professors whose research has led them and the Harvard patent office into entrepreneurial nanotechnology include Thomas Rueckes (Nantero) and Charles M. Lieber and Hongkun Park (Nanosys).
Entire contents, Copyright © 2007 The New York Times. All rights reserved.
Alert Triggered for MTS Systems Corp
MTSC Reached a New 52 Week High at $44.50
MTSC rose 1.3% to a new 52 week high of $44.50. During the last 52 weeks, MTSC's price has ranged from $30.86 on September 22, 2006 to today's high of $44.50.
Alert Triggered for Arrowhead Research Corp
ARWR Reached a New 52 Week High at $7.69
ARWR rose 0.1% to a new 52 week high of $7.69. During the last 52 weeks, ARWR's price has ranged from $3.55 on March 14, 2007 to today's high of $7.69.
Alert Triggered for Arrowhead Research Corp
ARWR Reached a New 52 Week High at $7.40
ARWR rose 2.9% to a new 52 week high of $7.40. During the last 52 weeks, ARWR's price has ranged from $3.55 on March 14, 2007 to today's high of $7.40.
Alert Triggered for Arrowhead Research Corp
ARWR Reached a New 52 Week High at $7.28
ARWR rose 9.5% to a new 52 week high of $7.28. During the last 52 weeks, ARWR's price has ranged from $3.55 on March 14, 2007 to today's high of $7.28.
Alert Triggered for MTS Systems Corp
MTSC Reached a New 52 Week High at $44.32
MTSC rose 0.0% to a new 52 week high of $44.32. During the last 52 weeks, MTSC's price has ranged from $30.86 on September 22, 2006 to today's high of $44.32.
SOTK 1.10 with 14 million shs. o/s and 23 straight profitable quarters out with news after the close now shipping new cardiac stent coating system:
Sono-Tek Corporation Announces the MediCoat PSI, Peripheral Stent Coating System
MILTON, N.Y., May 29, 2007 /PRNewswire-FirstCall via COMTEX/ -- Sono-Tek Corporation (OTC Bulletin Board: SOTK), announced today the release of the MediCoat PSI. The MediCoat PSI offers the same cutting-edge precision stent coating features as the well established MediCoat DES systems used for coating cardiac stents. The new PSI model is ideal for coating large peripheral stents, and it is capable of coating, in one cycle, multiple stents up to a cumulative length of 8 inches.
MediCoat PSI incorporates Sono-Tek's proven MicroMist ultrasonic atomizing nozzle, and provides stent motion that assures complete coverage of large vascular stents.
Sono-Tek CEO and President, Dr. Christopher L. Coccio stated, "The MediCoat PSI, is a logical addition to the family of Sono-Tek stent coating systems. The application of applying drug/polymer coatings onto peripheral stents is in its infancy; however, several of the large stent manufacturers are pursuing this option. Many of these companies already use MediCoat DES systems from Sono-Tek to coat their cardiac stents. Providing them with solutions for use with peripheral stents is ideal for us. Our first system was recently sold and well received by the customer."
More information on the new SonoDry MediCoat PSI can be found at the following location on our website: http://www.sono-tek.com/biomedical/medicoat_psi.php, or by contacting Dr. Christopher L. Coccio at 845-795-2020.
Sono-Tek Corporation is a leading developer and manufacturer of liquid spray products based on its proprietary ultrasonic nozzle technology. Founded in 1975, the Company's products have long been recognized for their performance, quality and reliability.
This press release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions; political, regulatory, competitive and technological developments affecting the Company's operations or the demand for its products; timely development and market acceptance of new products; adequacy of financing; capacity additions and the ability to enforce patents. We refer you to documents that the company files with the Securities and Exchange Commission, which includes Form 10-KSB and Form 10-QSBs containing additional important information.
SOURCE Sono-Tek Corporation
CONTACT: Christopher L. Coccio of Sono-Tek Corporation, +1-845-795-2020
URL: http://www.sono-tek.com
http://www.sono-tek.com/biomedical/medicoat_psi.php
http://www.prnewswire.com
www.prnewswire.com
Alert Triggered for MTS Systems Corp
MTSC Reached a New 52 Week High at $44.18
MTSC rose 1.9% to a new 52 week high of $44.18. During the last 52 weeks, MTSC's price has ranged from $30.86 on September 22, 2006 to today's high of $44.18.
Alert Triggered for MTS Systems Corp
MTSC Reached a New 52 Week High at $44.08
MTSC rose 0.1% to a new 52 week high of $44.08. During the last 52 weeks, MTSC's price has ranged from $30.86 on September 22, 2006 to today's high of $44.08.
Please note you will receive only one "New 52 Week High" alert per day for MTS Systems Corp.
MFIC is undervalued!
MFIC is a leading-edge technology company whose equipment is found in 3,500 to 4,000 patent filings worldwide. They have an installed base of over 3,000 Microfluidizers with every major drug and biotech company which are now in a position to buy their next-generation, cutting-edge MRT equipment. They are a leader in the emerging field of nanotechnology which is projected to grow by quantum leaps in the next decade. MFIC has a very low float and tiny $17 Million market cap which is dwarfed by more than 10 times by other nanotech stocks that have never sold a product or even booked a profit.
Alert Triggered for Lumera Corp
Lumera Corp (LMRA) Price Crossed Above Its 60 Day Moving Average
LMRA crossed above its 60 day moving average of $4.63 with a trade of $5.25 at 9:31 AM EDT, up 11.5% from the moving average. It is currently trading strongly higher on the day, up 1.6% to $5.15, on volume of 363,499, which is especially heavy given that there are still several hours left in the trading day.
Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for LMRA.
MFIC 1.50 and 10 million shares outstanding announces major breakthrough technology product for its Fortune 500 pharmaceutical & biotech customers:
MFIC Corporation Unveils Breakthrough Microfluidics Reaction Technology for Drug Formulation
Wednesday May 23, 8:00 am ET
NEWTON, Mass.--(BUSINESS WIRE)--(Symbol OTCBB: MFIC): MFIC Corporation presented a significant discovery in their development program called Microfluidics Reaction Technology (MRT) during a poster presentation at the Nano Science and Technology Institute (NSTI) Nanotech 2007 Conference on Tuesday, May 22, 2007. MRT provides the next-generation in nanosuspension processes to help pharmaceutical and biotechnology companies develop and ultimately manufacture difficult to formulate drugs.
"The advent of MRT could potentially unlock uncounted drugs, vaccines and drug delivery systems that to date could not be formulated. It provides a critical advancement in the field of drug formulation and positions MFIC as a clear technology leader," said Bob Bruno, President & COO. "We anticipate introducing a line of equipment to facilitate the MRT process in the fourth quarter of this year, providing our customers with an additional effective and efficient solution for the creation of promising, new therapeutics."
MRT advances the manufacturing of nanosuspensions "bottom up" by chemical reactions or physical processes such as crystallization. It has been demonstrated for a variety of drugs using solvent and anti-solvent crystallization. This approach allows for a greater ability to control the growth rates of nanoparticles to produce uniform, optimally-sized nanoparticles in a more efficient, cost-effective manner. Conventional "top down" processes reduce particle sizes to the nano-level through a process of wet-milling, homogenization, micronization, and other techniques. MRT works by pumping liquid reactants through a coaxial feed system within a Microfluidizer® reaction chamber, which is based on impinging jet principals. The system provides precise control of the feed rate and mixing location.
"Through the use of MRT, MFIC engineers were able to produce nanosuspensions for several drugs, including two antibiotics, an antihistamine, an anticonvulsant and a non-steroidal anti-inflammatory," said Dr. Thomai Panagiotou, Vice President of Research and Development and the lead investigator and presenter of the study. "Importantly, MRT was demonstrated to be more effective in producing nanosuspensions than standard, particle size reducing methods," concluded Dr. Panagiotou.
The MRT technology and applications are outlined in the poster presented at the NSTI meeting. The poster will be accessible later this week on the Company's Web site at www.microfluidicscorp.com/.
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR and MRT nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
Contact:
MFIC Corporation
Robert P. Bruno, President & COO
or
Jack M. Swig, Investor Relations
617-969-5452
Fax: 617-965-1213
info@mfics.com
www.mficcorp.com
--------------------------------------------------------------------------------
Source: MFIC Corporation
LMRA 4.62 - This deal with Fujitsu following the one with Lockheed Martin is the start of the commercialization of the Lumera nanotech product offerings:
Lumera Corporation Announces Order from Fujitsu Labs of America
BOTHELL, Wash.--(BUSINESS WIRE)--May 23, 2007--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, today announced a purchase order from Fujitsu Laboratories of America (FLA), at www.fla.fujitsu.com, for its electro-optic polymer modulators.
"We have been working with FLA in the field of optical interconnects, creating polymer modulator arrays that can work at data rates of 10 Gbps," said Dr. Raluca Dinu, Director of Lumera's Electro-Optic Business Unit. "We look forward to an ongoing relationship with them as they continue to develop innovative circuit board solutions."
FLA is performing research activity in the areas of optical interconnect development. In testing polymer optical modulators FLA found Lumera's electro-optical polymer modulators offered high data rate connections. Fujitsu Limited has patent applications for a module or subsystem using a polymer modulator in such module or subsystem.
About Lumera
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
CONTACT: Investor Relations:
Lumera Corporation
Helene F. Jaillet, 425-398-6546
or
Media:
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Cell: 801-244-9600
SOURCE: Lumera Corporation
New nanotechnology kills cancer cells
SANTA CLARA, Calif., May 22 (UPI) -- U.S. scientists have discovered a nanocomposite particle that can be constructed to kill cancer cells with the help of a laser.
By combining an organic matrix with metallic clusters that can absorb light, researchers found it's possible to incorporate such particles into cells and then destroy those targeted cells with a laser.
The scientists from the NanoBiotecnology Center at the Roswell Park Cancer Institute in Buffalo, N.Y., and the University of Michigan, were to present the research in Santa Clara, Calif., during the Nano Science and Technology Institute's Nanotech 2007 conference.
Alert Triggered for Arrowhead Research Corp
ARWR Reached a New 52 Week High at $7.25
ARWR rose 1.0% to a new 52 week high of $7.25. During the last 52 weeks, ARWR's price has ranged from $3.55 on March 14, 2007 to today's high of $7.25.
Alert Triggered for Arrowhead Research Corp
ARWR Reached a New 52 Week High at $7.19
ARWR rose 2.7% to a new 52 week high of $7.19. During the last 52 weeks, ARWR's price has ranged from $3.55 on March 14, 2007 to today's high of $7.19.
Luna Receives FDA Approval for Device
Monday May 21, 9:47 am ET
Luna Innovations Receives Food and Drug Administration Approval for EDAC Quantifier
ROANOKE, Va. (AP) -- Luna Innovations said Monday the Food and Drug Administration approved its EDAC Quantifier.
The device is designed to detect gaseous emboli, air bubbles or solid matter, that can enter the blood system during invasive medical procedures including cardiopulmonary bypass surgery. The device is available immediately, the company said.
Shares of Luna spiked $1.74, or 58 percent, to $4.74 in morning trading. The stock has ranged from $2.87 to $6.66 over the past year.
Alert Triggered for MTS Systems Corp
MTSC Reached a New 52 Week High at $43.93
MTSC rose 0.4% to a new 52 week high of $43.93. During the last 52 weeks, MTSC's price has ranged from $30.86 on September 22, 2006 to today's high of $43.93.
I would like to see TDON added to this board's list of nanotechnology stocks. The company has a very high potential new Electro-Optic polymer technology. Here is some starter info below. I also have set up a dedicated board for TDON discussion on iHub and welcome everyone to come over at your convenience.
----------------------------------------------------------
About Third-Order Nanotechnologies, Inc.(TDON)
http://finance.yahoo.com/q?s=tdon.pk
Third-Order Nanotechnologies is emerging from a development stage research and development company with commercial introduction of its high-activity, high-stability organic polymers for applications in electro-optic and all- optical device markets. Electro-optic devices convert data from electric signals into optical signals for use in high speed communications systems and in optical interconnects for high-speed data transfer. All-optic devices, while still some time from commercial application, control the flow of light with optical (not electric) signals.
Historically, no one has been able to solve the problem of polymer stability, meaning that as polymers became more powerful, their stability decreases. Third-Order Nanotechnologies undertook a radical departure from conventional polymer science, and appears to have solved the stability issue surrounding EO polymer. Apart from its demonstrated molecular stability and high performance, the Company's technology is also highly scalable and significantly less expensive to manufacture than competitive technologies.
The Company's technological advancements have been verified independently. Scientists at the University of Arizona's College of Optical Sciences, one of the leading optical science departments in the world, have confirmed that the Company's molecular design outperforms one of the industry's highest performance electro-optic systems by a factor as high as 650%. Additionally, Third-Order Nanotechnologies was named as the recipient of the prestigious Frost & Sullivan 2006 North American Electro-Optic Materials Technology Innovation of the Year Award.
Third-Order Nanotechnologies is on the verge of initial commercialization and there are an unlimited number of potential applications for the Company's technology in sectors including telecommunications, medical imaging, and government intelligence agencies.
34 Page Analyst Report (December, 2006): http://www.wallstreetresources.net/pdf/fc/TDON.pdf
8 Page Report from Equities Magazine (February, 2007):
http://www.equitiesmagazine.com/pdfs/research/third_order_nano_spot_report.pdf
Video of TDON Investor Presentation at Equities Conference (February 23, 2007):
http://www.visualwebcaster.com/VWP/SkinPlayer/Player.asp?e=38028&w=320&h=310&s=True&....
Company Address:
Third-Order Nanotechnologies, Inc.
2601 Annand Dr. #16
Wilmington, DE 19808
USA
Website: http://www.third-order.com
Phone: 302-388-1739
Fax: 302-998-4190
Country of Incorporation: USA
Year of Incorporation 1995
Officers:
Hal Bennett, CEO; Frederick Goetz Jr., President; Andrew Ashton, Senior VP; Frederick Goetz Sr, CTO
Fiscal Year End: December 31
Outstanding Shares: 30,188,535 as of April, 2007
Alert Triggered for Lumera Corp
LMRA's Trading Volume Exceeded Daily Average by 201.6%
LMRA is up $0.47 or 11.14% to $4.69 on heavy volume that exceeded its daily average by 201.6%. This performance is better than the broader averages as the S&P 500 is up 0.49% on the day.
Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for Lumera Corp.
MFIC Corporation to Present at Upcoming Financial Conferences
Thursday May 17, 8:24 pm ET
NEWTON, Mass.--(BUSINESS WIRE)--(Symbol OTCBB: MFIC): MFIC Corporation, a leader in advanced equipment used widely in the pharmaceutical and biotechnology industries to process and formulate innovative and improved products, announced today that the Company will present at two upcoming financial conferences in New York City. Senior management will discuss corporate initiatives, an upcoming product launch and research, development activities, and other recent developments.
Presentation details are as follows:
Tuesday, May 22, 2007 at 9:50 a.m. ET: Wall Street Analyst Forum's 18th Annual Analyst Conference, New York City, Princeton Club at W. 43rd Street
Thursday, May 24, 2007 at 10:20 a.m. ET: Friedland Investment Events LLC's Undervalued Equity Conference, New York City, Doubletree Hotel at 569 Lexington Avenue
About MFIC Corporation:
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Contact:
Robert P. Bruno, President & COO
or
Jack M. Swig, Investor Relations
617-969-5452
Fax: 617-965-1213
info@mfics.com
www.mficcorp.com
--------------------------------------------------------------------------------
Source: MFIC Corporation
MFIC to present at The Wall Street Analyst Forum on May 22, 2007:
Since 1988, The Wall Street Analyst Forum has been a sponsor of four annual analyst conferences for the CEO/CFO's of NYSE/NASDAQ/AMEX corporations in New York, Boston and London.
Scheduled companies May 22, 2007: Insert Therapeutics (NASDAQ: ARWR), MFIC Corp. (OTCBB: MFIC), Neural Stem, Inc. (OTCBB: NRLS), Cardium Therapeutics, Inc. (OTCBB: CDTP), AspenBio Pharma, Inc. (OTCBB: APNB) Innovive Pharmaceuticals (OTCBB: IVPH), Aradigm Corporation (OTCBB: ARDM), Avicena Group (OTCBB: AVGO). May 23, 2007: Heska Corporation (NASDAQ: HSKA), HealthSonix Inc. (Pink Sheet: HSXI), Capital Senior Living Corp. (NYSE: CSU), Sharps Compliance Corp. (OTCBB: SCOM), Castle Brands Inc. (AMEX: ROX). May 24, 2007: GVI Security Solutions, Inc. (OTCBB: GVSS), AeroMechanical Services Ltd. (TSX VENTURE: AMA.V), Optionable Inc. (OTCBB: OPBL), Bank of Internet USA (NASDAQ: BOFI).
Mapping the New U.S. ''Nano Metro'' Economy
05.17.07, 4:38 AM ET
Business Wire - Press Release
With nanotechnology poised to be the globe's next big economic driver, five U.S. cities have emerged as the country's top "Nano Metro" locations--areas with the nation's highest concentration of nanotech companies, universities, research laboratories, and organizations.
Three leading "Nano Metro" centers--San Jose, San Francisco and Oakland--are in California, the state emerging as the domestic frontrunner in nanotechnology competition. The other two--Boston and Middlesex-Essex--are in Massachusetts.
This information is on view as part of a new interactive map displaying the growing "Nano Metro" landscape. The map and accompanying analysis--presented by the Wilson Center's Project on Emerging Nanotechnologies--depicts and ranks cities and states by numbers of companies, nanotechnology academic and government research centers, organizations, business sectors, and much more. It is powered by Google Maps(R) and is available at no cost online at www.nanotechproject.org/121.
Nanotechnology Map Highlights:
-- The top 4 nanotechnology states are: California, Massachusetts, New York and Texas.
-- The top 5 "Nano Metro" areas are: San Jose, CA; Boston, MA; San Francisco, CA; Oakland, CA; and Middlesex-Essex, MA.
-- Nanotechnology companies are working in 3 main sectors: materials, medicine and health, and tools and instruments.
-- The number of universities and government laboratories working on some aspect of nanotechnology is significant, with 138 identified.
-- In all, 47 of 50 states and the District of Columbia contain at least one company, university, government laboratory, or organization working in nanotechnology, showing that nanotechnology activity is occurring throughout the United States.
In 2006, according to Lux Research, governments, corporations and venture capitalists worldwide spent $12.4 billion on nanotechnology research and development (R&D)--up almost 30 percent from 2005. By 2014, Lux estimates $2.6 trillion in manufactured goods will incorporate nanotechnology--or about 15 percent of total global output.
"Nanotechnology is usually seen as a worldwide or national enterprise, with the U.S. government alone investing $6.8 billion in nanotech R&D over the last decade. But what some describe as 'The Next Industrial Revolution,' is actually taking place at a local and state level," said Project on Emerging Nanotechnologies Director David Rejeski. "The top 20 U.S. 'Nano Metro' areas include cities as different as Raleigh, NC, Albuquerque, NM, and New York, NY."
"This map is drawn from publicly available information in key databases and it is not complete," according to Rejeski. "We know there is a lot more nanotech commercial and research activity than is reflected here. But this is a first attempt to show that nanotechnology is not a Silicon Valley or Boston Route 128 phenomena. Nanotechnology increasingly is on Main Street everywhere. As the Project receives new data, we plan to update the map to provide the best possible depiction of this country's emerging nanotechnology landscape."
Nanotechnology is the ability to measure, see, manipulate and manufacture things usually between 1 and 100 nanometers (nm). A nanometer is one billionth of a meter. A human hair is roughly 100,000 nanometers wide. The limit of the human eye's capacity to see without a microscope is about 10,000 nm.
The Project on Emerging Nanotechnologies is an initiative launched by the Woodrow Wilson International Center for Scholars and The Pew Charitable Trusts in 2005. It is dedicated to helping business, government and the public anticipate and manage possible health and environmental implications of nanotechnology.
MFIC Corporation Announces First Quarter Results
Tuesday May 15, 11:56 am ET
NEWTON, Mass.--(BUSINESS WIRE)--MFIC Corporation (OTCBB: MFIC - News) today reported revenues for the quarter ended March 31, 2007 of $2.80 million, representing a decrease of $350,000, or approximately 11%, compared with revenues of $3.15 million for the quarter ended March 31, 2006.
For the quarter ended March 31, 2007, the Company posted a net loss of $417,000, or $.04 per diluted share, as compared with net income of $42,000, or $0.00 per share, for the quarter ended March 31, 2006. The first quarter 2007 included no income tax provision while the first quarter of 2006 included an income tax expense of $27,000.
Operating expenses increased by $401,000, or 11.9% to $2.04 million for the quarter ended March 31, 2007 from $1.64 million for the quarter ended March 31, 2006. The increase was primarily due to additional staffing and programs undertaken in 2006 and is at a level that is consistent with that of the fourth quarter of 2006.
The Company's order backlog at March 31, 2007 was $2.94 million, a decrease of approximately 14.7% from $3.45 million at March 31, 2006, and a decrease of 2.3% from $3.01 million at December 31, 2006. The decrease in backlog reflects a slow down in orders, primarily for custom production units, which continues in the second quarter.
Robert P. Bruno, President & COO stated "First quarter 2007 revenues were significantly impacted by delays in shipping of two production Microfluidizer processor systems awaiting customer acceptance, valued in the aggregate at approximately $644,000, and four smaller units having an aggregate value of approximately $172,000, which were awaiting credit clearance. The six units are anticipated to be booked as revenue in the second quarter of 2007."
First Quarter 2007 Company Highlights
During the quarter, MFIC:
Sold a high number of laboratory units and experienced strong demand for such units, in particular for the improved Model M-110EH-30 introduced in late 2005.
Completed production of our first new BioPharmaceutical integrated platform system including Constant Pressure, Steam In Place and extensive electronic operating controls and real-time data archiving systems all within a single unit.
Completed development of a soon-to-be-introduced, new laboratory unit with currently unavailable features and capabilities.
Achieved a significant breakthrough discovery in our MMR program; Microfluidics Reaction Technology (MRT) enables nanoparticle formulation for drug and other formulations utilizing our proven and cost-effective Microfluidizer® processor equipment. Initial publication of research will be made in May at the 2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007.
Was selected as a global supplier by a major pharmaceutical company for their manufacturing plants worldwide.
Notice to Investors/Stockholders
MFIC will hold a conference call at 1:00 PM Eastern Time on Wednesday, May 16, 2007 to discuss first quarter financial results. The domestic call in number is (866) 550-6338 or internationally (347) 284-6930 and the Confirmation Code is 8540195. Management's discussion will be followed by a question and answer period. For those who cannot listen and participate in the live event, a replay of the call will be available on the Company's website: www.mficcorp.com.
MFIC CORPORATION
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid structures available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
MFIC CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
----------------------------------------------------------------------
(Unaudited - in thousands except share and per amounts)
----------------------------------------------------------------------
Three months ended
March 31,
(Unaudited)
=======================
2007 2006
---------------------------------------------- ----------- -----------
Revenues $2,801 $3,151
---------------------------------------------- ----------- -----------
Cost of goods sold 1,194 1,447
---------------------------------------------- =========== ===========
Gross profit 1,607 1,704
---------------------------------------------- ----------- -----------
Operating expenses:
---------------------------------------------- ----------- -----------
Research and development 536 397
---------------------------------------------- ----------- -----------
Selling 824 616
---------------------------------------------- ----------- -----------
General and administrative 677 623
---------------------------------------------- =========== ===========
Total operating expenses 2,037 1,636
---------------------------------------------- =========== ===========
(Loss) income from operations (430) 68
---------------------------------------------- ----------- -----------
Interest expense (8) (9)
---------------------------------------------- ----------- -----------
Interest income 21 10
---------------------------------------------- =========== ===========
(Loss) income before income tax provision (417) 69
---------------------------------------------- ----------- -----------
Income tax provision - (27)
---------------------------------------------- =========== ===========
Net (loss) income $(417) $42
---------------------------------------------- =========== ===========
Net (loss) income per common share:
---------------------------------------------- ----------- -----------
Basic $(0.04) $0.00
---------------------------------------------- ----------- -----------
Diluted $(0.04) $0.00
---------------------------------------------- ----------- -----------
Weighted average number of common and
common equivalent shares outstanding:
---------------------------------------------- ----------- -----------
Basic 10,123,084 9,952,837
---------------------------------------------- ----------- -----------
Diluted 10,123,084 10,590,101
---------------------------------------------- ----------- -----------
Summary Consolidated Unaudited Balance Sheet Information
(Unaudited - in thousands)
----------------------------------------------------------------------
March December
31, 31,
2007 2006
----------------------------------------------------- ------- --------
Current Assets $7,358 $7,857
----------------------------------------------------- ------- --------
Current Liabilities $2,088 $2,213
----------------------------------------------------- ------- --------
Total Stockholders' Equity $5,622 $5,948
----------------------------------------------------- ------- --------
Forward Looking Statement:
Management believes that this release contains forward-looking statements that are subject to certain risks and uncertainties including statements relating to the Company's plan to attain and/or increase operating profitability and/or to achieve net profitability. Such statements are based on management's current expectations and are subject to a number of factors and uncertainties that could cause actual results achieved by the Company to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that the actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including but not limited to the following risks and uncertainties: (i) whether the performance advantages of the Company's Microfluidizer® materials processing equipment will be realized commercially or that a commercial market for the equipment will continue to develop, (ii) whether the performance advantages of the Company's MMR nanoparticle production systems will be realized commercially, (iii) whether the Company will be able to increase its market penetration and market share, (iv) whether the timing of orders will significantly affect quarterly revenues and resulting net income results for particular quarters which may cause increased volatility in the Company's stock price, and (v) whether the Company will have access to sufficient working capital through continued and improving cash flow from sales, and ongoing borrowing availability, the latter being subject to the Company's ability to comply with the covenants and terms of its loan agreement with its senior lender.
Contact:
MFIC Corporation
Robert P. Bruno, President & COO
or
Jack M. Swig, Investor Relations
617-969-5452
info@mfics.com
--------------------------------------------------------------------------------
Source: MFIC Corporation
CVV's 10th straight quarter of profitability:
CVD Equipment Corporation Announces First Quarter Results
Monday May 14, 6:47 pm ET
RONKONKOMA, N.Y., May 14 /PRNewswire-FirstCall/ -- CVD Equipment Corporation (Amex: CVV - News) today announced that it has achieved profitable results for the tenth consecutive quarter.
Revenue for the first quarter ending March 31, 2007 was approximately $3,811,000, compared to $3,211,000 for the quarter ending March 31, 2006, an increase of 18.7% as we continue to experience an increasing demand for our products. The overall gross profit percentage decreased slightly to 33.0% for the current quarter compared to 33.3% for the same period one year ago. As a result of our stepped-up efforts to increase our presence at trade shows in order to effectuate our sales expansion program, selling and shipping expenses increased by approximately $81,000 or 41.4% during the current three month period ending March 31, 2007 compared to the same respective period one year ago. General and administrative expenses for the three months ending March 31, 2007 increased by approximately $55,000 or 7.7% compared to the three months ending March 31, 2006 due to increases in benefit costs, insurance and energy costs.
Our operating income for the current quarter ending March 31, 2007 was $204,000 compared to $155,000 for the quarter ending March 31, 2006. Net income for the current quarter was approximately $96,000 or $0.03 per share basic and diluted compared to $113,000 or $0.04 basic and $0.03 diluted earnings per share for the quarter ending March 31, 2006. This decrease was primarily due to two factors: the receipt of $70,000 during the 1st quarter 2006, which was previously written off in 2004; and an increase in expenses in the current quarter associated with the expansion program we first discussed in the December 31, 2006 Form 10-K, to broaden the First Nano product line and pursue a significantly larger share of the R&D market and have begun to experience an increase in design and manufacturing costs associated with this program.
As of March 31, 2007 the Company's backlog was approximately $2,143,000, a decrease of $1,422,000 or 40.0% compared to $3,565,000 at December 31, 2006. Timing for completion of the backlog varies depending on the product mix, however, there is generally a one to six month lag in the completion and shipping of backlogged product. Backlog from quarter to quarter can vary based on the timing of order placements and shipments.
Leonard Rosenbaum, President and Chief Executive Officer stated, "We are pleased with the 18.9% increase in sales during the first quarter. Additionally, the success of our First Nano laboratory growing the record shattering long CNT array and for long CNT arrays on large diameter substrates (see Form 8-K filed on April 30, 2007) is very promising for bringing this technology from the research laboratory into production.
We anticipate that the additional sales, engineering and manufacturing expenditures we are currently incurring to broaden the First Nano product line will further add to the long term revenue and increased profitability of the company.
The decrease in backlog on March 31, 2007 as compared to March 31, 2006 is due to timing of order placements and shipments. Our quotation activity is up, and our order levels in April keep us on track to continue the revenue growth seen in 1st quarter 2007 and for all of 2006. We expect the expansion programs we have initiated will continue to fuel this growth.
CVD Equipment Corporation, is a global designer, manufacturer and supplier of equipment for use in manufacturing semiconductors, solar cells, carbon nanotubes, nanowires and equipment for surface mounting of components onto printed circuit boards,
Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in CVD Equipment Corporation's filings with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on CVD Equipment Corporation's website does not constitute a part of this release.
CVD Equipment Corporation
Comparative Operating Results for the Three Months ended March 31,
2007 2006
Revenue $3,811,000 $3,211,000
Operating income 204,000 155,000
Net income 96,000 113,000
Net income
Per share basic $0.03 $0.04
Per share diluted 0.03 0.03
Weighted average shares of
common stock outstanding
Basic 3,284,589 3,132,689
Diluted 3,413,792 3,302,226
--------------------------------------------------------------------------------
Source: CVD Equipment Corporation
Nanotechnology Now Used in Nearly 500 Everyday Products
5/15/2007 9:37:38 AM
The number of consumer products using nanotechnology has more than doubled, from 212 to 475, in the 14 months since the Project on Emerging Nanotechnologies launched the world’s first online inventory of manufacturer-identified nanotech goods in March 2006. Clothing and cosmetics top the inventory at 77 and 75 products, respectively. A list of nanotechnology products that also includes bedding, jewelry, sporting goods, nutritional and personal care items is available free at http://www.nanotechproject.org/consumerproducts.
Nanotechnology Consumer Products Inventory Highlights:
The food and beverages category, including containers and dietary supplements, doubled to 61 products since last year.
Nanoscale silver is the most cited nanomaterial used. It is found in 95 products or 20 percent of the inventory. Carbon, including carbon nanotubes and fullerenes, is the second highest nanoscale material cited.
Merchandise from 20 countries is now represented. The United States leads internationally with 52 percent or 247 consumer products that contain nanotechnology. East Asia now boasts 123 products, a 58 percent increase over last year.
New products in the inventory include the Corsa Nanotech Ice Axe which uses an innovative Sandvik Nanoflex® steel alloy that’s 20 percent lighter than normal steel and up to 60 percent stronger. There’s also MaatShop™ Crystal Clear Nano Silver—a clear liquid dietary supplement which peddles protection against colds, flu and hundreds of diseases, even anthrax.
While polls show most Americans know little or nothing about nanotechnology, in 2005 nanotechnology was incorporated into more than $30 billion in manufactured goods. By 2014, Lux Research estimates $2.6 trillion in manufactured goods will incorporate nanotechnology—or about 15 percent of total global output.
“The use of nanotechnology in consumer products and industrial applications is growing rapidly, with the products listed in the inventory showing just the tip of the iceberg,” said Project on Emerging Nanotechnologies science advisor Andrew Maynard. “How consumers respond to these early products—in food, electronics, health care, clothing and cars—will be a litmus test for broader market acceptance of nanotechnologies in the future.”
Nanotechnology is the ability to measure, see, manipulate and manufacture things usually between 1 and 100 nanometers (nm). A nanometer is one billionth of a meter. A human hair is roughly 100,000 nanometers wide. The limit of the human eye’s capacity to see without a microscope is about 10,000 nm.
TDON beat down to levels not see since the last flurry of PRs and interviews.
I'll be buying from here on down.
Nanopackaging Is Intelligent, Smart And Safe Life. New World Study By Hkc22.com/beijing Office
According to a new study by Helmut Kaiser Consultancy, Nanotechnology has been significantly increasing its impact on the food and beverage packaging industry during last three years,US $ 980 million in 2006 worldwide.
Source: helmut kaiser consultancy
May 14, 2007 01:17:36
According to a new market study developed by Helmut Kaiser Consultancy (www.hkc22.com). Nanotechnology has been significantly increasing its impact on the food and beverage packaging industry during last three years. The sales of the nano-related packaging products have been rising from US$ 150 million in 2002 to $ 860 million in 2004 , 980 in 2006 worldwide. Nonetheless, compared with the over $100 billion food and beverage packaging industry, the growth potential of the nanopackaging is still enormous. It is predicted that nanotechnology will change 25% of the food packaging business in the next decade, that means a yearly over $ 30 billion market. The packaging will become more and more a service and try to meet as many customers´ requirements as possible. Simple traditional “packing” is to be replaced with multi-functional intelligent methods to improve the food quality.
The rocketing market growth comes mainly from the rapid multiplication of the applications employing nanotechnology. While there were less than 40 nanopackaging products in the market three years ago, this number has been going beyond 400 today. Present major market trends include enhancing the performance of packaging materials, prolonging shelf life, antimicrobial packaging and interactive packaging.
Nanotechnology enables the designers to alter the structure of the materials on the molecular scale, to give the materials desired properties. With different nanostructure, the plastics can obtain various gas/water vapor permeabilities to fit the requirements of reserving fruit, vegetable, beverage, wine and other food. By adding nanoparticles, people can also produce bottles and packages with more light and fire resistantance, stronger mechanical and thermal performance, and less gas absorption. These properties can significantly increase the shelf life, efficiently preserve flavour & colour, and facilitate transportion & usage. Further, nanostructured film can effectively prevent the food from the invasion of bacteria and microorganism and ensure the food safety. With embedded nanosensors in the packaging, consumers will be able to “read” the food inside. Sensors can alarm us before the food goes rotten or can inform us the exact nutrition status contained in the contents.
In the long run, nanotechnology is going to change the fabrication of the whole packaging industry. Processing the atoms and molecules will realize zero-emission recycle and save natural resources. Self-assembly will in the end hugely reduce the fabrication costs and infrastructure. More flexible packaging methods will provide the consumers with fresher and customized products.
Nanopackaging has attracted the attention of industrial leaders, governments and research institutes. Multi-national companies, such as Krafts, Henkel, Bayer, Kodak, Budweiser, Pepsi, to name just a few, all have their R&D projects concerning the application of nanotechnology in the field of food & beverage packaging. NASA, US Department of Defense and leading European institutes show their special interests in the related segments as well. It is worthy of noticing that China and Taiwan have already taken a firm foothold in this market and are poised to be challenging competitors in this market.
The study http://www.hkc22.com/Nanofood2040.html , developed by Helmut Kaiser Consultancy is based on constant market watch, broad surveys and interviews during last three years. The study includes analysis of the market development up to 2015 by countries and by market segments, detailed listing of the present and potential market applications, and description of the state of science and the technology trends, together with a list of related patents. Governmental strategy & support, ethical & social issues are parts of the study as well. A comprehensive collection of the competitors and their activities enables the readers to get insight of what is happening in every company and every country
Related study about nanofood: http://www.hkc22.com/nanofood.html
helmut kaiser, consultancy, Zurich, Beijing 2007, 0049 7071 67001 and
hku-tuebingen@t-online.de
CVV - National Science Foundation PR News Today:
http://www.nsf.gov/news/news_summ.jsp?cntn_id=108992&org=NSF&from=news
Fabric coating with nanomaterials is an area that SOTK has entered:
Nano Apparel Prevents Colds and Flu
Source: The Engineer
Date Published: May 04, 2007
Fashion designers and fibre scientists at Cornell University have designed a garment that can prevent colds and flu and never needs washing.
Fashion designers and fibre scientists at Cornell University have designed a garment that can prevent colds and flu and never needs washing. The team has also created another that destroys harmful gases and protects the wearer from smog and air pollution.
The two-toned gold dress and metallic denim jacket, featured at the April 21 Cornell Design League fashion show, contain cotton fabrics coated with nanoparticles that give them functional qualities never before seen in the fashion world.
Designed by Olivia Ong in the College of Human Ecology's Department of Fiber Science and Apparel Design, the garments were infused with their unusual qualities by fibre science assistant professor Juan Hinestroza and his postdoctoral researcher Hong Dong. Apparel design assistant professor Van Dyke Lewis launched the collaboration by introducing Ong to Hinestroza several months ago.
'We think this is one of the first times that nanotechnology has entered the fashion world,' Hinestroza said. He noted one drawback may be the garments' price: one square yard of nano-treated cotton would cost about $10,000.
Ong's dress and jacket are part of her original fashion line called "Glitterati". They are packed with electrostatically charged nanoparticles creating a protective shield around the cotton fibres in the top part of the dress, and the sleeves, hood and pockets of the jacket.
Dong explained that the fabrics were created by dipping them in solutions containing nanoparticles synthesised in Hinestroza's lab. The resultant colours are not the product of dyes, but rather, reflections of manipulation of particle size or arrangement.
The upper portion of the dress contains cotton coated with silver nanoparticles. Dong first created positively charged cotton fibres using ammonium- and epoxy-based reactions, inducing positive ionisation. The silver particles, about 10-20 nanometres across were synthesised in citric acid, which prevented nanoparticle agglomeration.
Dipping the positively charged cotton into the negatively charged silver nanoparticle solution resulted in the particles clinging to the cotton fibres.
Silver possesses natural antibacterial qualities that are strengthened at the nanoscale, giving Ong's dress the ability to deactivate many harmful bacteria and viruses. The silver infusion also reduces the need to wash the garment, since it destroys bacteria, and the small size of the particles prevents soiling and stains.
The denim jacket includes a hood, sleeves and pockets with soft, grey tweed cotton embedded with palladium nanoparticles, about 5-10 nanometres in length. To create the material, Dong placed negatively charged palladium crystals onto positively charged cotton fibres.
Ong incorporated the resultant cotton fibre into a jacket with the ability to oxidise smog. Such properties would be useful for someone with allergies, or for protecting themselves from harmful gases in the contaminated air, such as in a crowded or polluted city.
Design student Olivia Ong hugs two garments, treated with metallic nanoparticles through a collaboration with fibre scientists Juan Hinestroza and Hong Dong, that she designed as part of her fashion line, "Glitterati"
Lumera Reports First Quarter 2007 Results and Updates on Product Development Progress
BOTHELL, Wash., May 03, 2007 (BUSINESS WIRE) -- Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field of nanotechnology, today reported financial results for the first quarter 2007 and released information regarding its current product development progress.
Revenues totaled $860,000 for the three months ended March 31, 2007 compared with $503,000 for the same period in 2006, a 71 percent increase over the prior year. Lumera's net loss totaled $2,696,000 or $0.13 per share for the three months ended March 31, 2007 compared with $3,120,000 or $0.19 per share for the same period in 2006.
"Lumera's first quarter is an indication of our continued progress forward," said Lumera Chief Executive Officer Tom Mino. "Increased revenue from government contracts resulted in the improved financial performance from a year ago. We've also entered into agreements in both business units that will enable us to continue building on our progress."
Summary Discussion of Product Development
Lumera develops proprietary polymer materials which are used in bioscience products and in electro-optic devices further detailed in the market summaries below.
Bioscience
Lumera is developing label free high throughput methods targeted at the biological and medical research markets.
Early in the quarter, Lumera announced that Dr. Josh LaBaer of the Harvard Institute of Proteomics presented his early research results using the ProteomicProcessor(TM) at the PEPTalk meeting in San Diego. Dr. LaBaer reported the successful integration of Harvard's NAPPA protein array methodology on Lumera's chip surface and, together, Lumera and Dr. LaBaer's group are working on building an array of kinase proteins.
Also during the quarter, the Company announced an important application for its ProteomicProcessor(TM) developed by the Institute for Systems Biology. The application allowed researchers to identify a novel biomarker panel associated with liver toxicity in mice. This development potentially opens a new avenue demonstrating how the instrument could be used in biomarker discovery.
Electro-Optics
Lumera is developing a new generation of electro-optic modulators and other devices for optical networks and systems based on proprietary polymer materials.
During the quarter, the Company announced it had received a purchase order from Lockheed Martin and entered into an agreement with Lockheed for Lumera's high electro-optic activity materials. The term of the agreement ends December 31, 2007, at which time Lockheed Martin will advise Lumera of its intentions regarding a commercial license for the materials.
Also during the quarter, Lumera announced that it had been awarded an extension to a U.S. government contract to continue development of technologically advanced wideband optical modulators. The twelve month contract is valued at approximately $1.15 million. The overall contract value has now reached approximately $6.9 million.
Summary Financial Discussion
Revenues totaled $860,000 for the three months ended March 31, 2007 compared with $503,000 for the same period in 2006, a 71 percent increase over the prior year. Government contract revenue totaled $775,000 for the current quarter, in increase of $292,000 from $483,000 in 2006 due primarily to higher billings on two of our contracts.
Product revenues totaled $85,000 for the current quarter, reflecting sales of electro-optic modulators. Backlog on our government contracts totaled $2,048,000 at March 31, 2007.
Operating expenses for the three months ended March 31, 2007, decreased by $139,000 to $3,434,000 compared to $3,573,000 for the same period in 2006. Research and Development expense, which totaled $1,271,000 for the three months ended March 31, 2007, decreased by $307,000, or 19 percent, from $1,578,000 for the same period in 2006 due to increased government contract activities resulting in higher levels of labor and related overhead costs being allocated to the cost of contract revenues and lower depreciation costs as our asset base becomes more fully depreciated. Marketing, general and administrative expense, which totaled $2,163,000 for the three months ended March 31, 2007, increased by $168,000, or 8 percent, from the same period in 2006 due primarily to cash compensation costs associated with additional sales and marketing and administrative personnel and increased consulting fees.
Lumera's net loss totaled $2,696,000 or $0.13 per share for the three months ended March 31, 2007, compared with $3,120,000, or $0.19 per share for the same period in 2006.
Lumera, which ended the quarter with $24.1 million in cash and investment securities, used $2.2 million in cash to fund operations and working capital requirements during the three months ended March 31, 2007, a decrease of $605,000 over the same period in 2006. Capital expenditures, which include leasehold and related capital improvements, totaled $71,000 for the first quarter of 2007, down from $317,000 during the same period in 2006.
Conference Call
Lumera will host a conference call to discuss its third quarter of 2006 financial results on Thursday, May 3 at 4:30 p.m. EDT. The call will be broadcast over the Internet and can be accessed from the company's web site at www.lumera.com. Additionally, U.S. participants may join the conference call by dialing 800.638.4817 ten minutes prior to the start of the conference. International participants can dial 617.614.3943. The conference passcode number is 23714654. A telephone replay of the call will be available through May 10, and can be accessed by dialing 888-286-8010 (for U.S. participants) or 617-801-6888 (for international participants). The replay passcode is 32065724. A replay of the conference call will be available on the company's web site.
About Lumera
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit www.lumera.com.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
Lumera Corporation
Condensed Balance Sheets
(In thousands)
(Unaudited)
March 31, December 31,
Assets 2007 2006
------------ -------------
Current assets
Cash and cash equivalents $ 5,443 $ 10,521
Investment securities, available-for-
sale 18,659 15,788
Accounts Receivable, net of allowance 5 380
Costs and estimated earnings in excess
of billings on uncompleted contracts 380 338
Other current assets 462 600
------------ -------------
Total current assets 24,949 27,627
Property and equipment, net 2,612 2,759
Restricted Investments 700 700
Other Assets 46 46
------------ -------------
Total assets $ 28,307 $ 31,132
============ =============
Liabilities and Shareholders' equity
Current liabilities
Accounts payable $ 398 $ 850
Accrued liabilities 891 982
------------ -------------
Total current liabilities 1,289 1,832
Deferred rent, net of current portion 385 407
------------ -------------
Total current liabilities 1,674 2,239
Commitments and contingencies
Shareholders' equity
Common stock at par value 20 20
Additional paid-in capital 90,125 89,690
Accumulated other comprehensive loss 2 1
Accumulated deficit (63,514) (60,818)
------------ -------------
Total shareholders' equity 26,633 28,893
------------ -------------
Total liabilities and shareholders' equity $ 28,307 $ 31,132
============ =============
Statements of Operations
(In thousands, except earnings per share and share data)
(Unaudited)
Three months ended March 31,
----------------------------
2007 2006
-------------- -------------
Revenue $ 860 $ 503
Cost of revenue 443 258
-------------- -------------
Gross profit 417 245
-------------- -------------
Research and development expense 1,271 1,578
Marketing, general and administrative
expense 2,163 1,995
-------------- -------------
Total operating expenses 3,434 3,573
-------------- -------------
Loss from operations (3,017) (3,328)
Interest income 321 208
-------------- -------------
Net loss from operations $ (2,696) $ (3,120)
============== =============
Net loss per share-basic and diluted $ (0.13) $ (0.19)
============== =============
Weighted-average shares outstanding -
basic and diluted 20,055,352 16,757,005
============== =============
SOURCE: Lumera Corporation
Lumera Corporation
Helene F. Jaillet, 425-398-6546 (Investor Relations)
or
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155 (Media)
801-244-9600 cell
IBM unveils nanotechnology chip advance
Times Online, May 3, 2007
First use of "nanoscale materials" in computer chips boosts performance by 35% and is billed as huge advanceRhys Blakely
Tiny holes could prove to be the biggest advance in computer chip design in 40 years.
IBM, the technology giant, today unveiled a new technique for manufacturing computer processors that uses “nanoscale self-assembled materials” for the first time.
The process, which IBM says boosts a chip’s processing power by more than a third, uses a plastic-like polymer that spontaneously falls into a microscopic sieve-type structure – mimicking the way a snowflake forms.
The airless holes formed in the material have a width of 20 nanometres, or billionths of a metre – far smaller than could be formed by conventional machining techniques.
According to IBM, the technology, called Airgap, yields a 35 per cent increase in chip performance – or a cut in power consumption of 15 per cent.
It added that the advance is set to drive the equivalent of two generations of Moore's Law – the formulation that says, roughly, that computer power doubles per cost unit every two years – in a single step.
Such disruptive technologies are the must-have silver bullets of the chip sector – an area where margins are under massive pressure and Intel and AMD, the two biggest players, are locked in a fierce price war.
IBM said the technology could be added to existing manufacturing lines and applied to current chips. It expects to start using the technique in 2009, first on chips used in Its own servers and later on components it makes for other companies.
The results could also be included in the powerful Cell processor already used in Sony’s PlayStation 3 games console.
IBM said they the technology will be licensed to semiconductor partners including Advanced Micro Devices, the world’s second-largest chip maker, and Toshiba. It did not comment on whether Intel, the market leader, was involved in licensing talks.
The breakthrough was led by Dr Daniel Edelstein, one of IBM's engineering fellows and a pioneer in the semiconductor sector. He was a key figure in the industry's migration to copper wiring from aluminum a decade ago.
Dr Edelstein said: "This is the first time anyone has proven the ability to synthesize mass quantities of these self-assembled polymers."
The secret of IBM's latest breakthrough lies in moving the self-assembly process from the laboratory to a manufacturing environment in a way that can potentially yield millions of chips with consistent, high performance results.
NVEC Strong EPS report could jumpstart the nanotech sector:
NVECorp 4Q Rises Sharply, Rev Up 31% >NVEC
Dow Jones Newswires - May 02, 2007 5:51 PM ET
NVE Corp.'s (NVEC) fiscal fourth-quarter net income rose sharply to $1.55 million, or 33 cents a share, from $619,744, or 13 cents a share, a year earlier.
Revenue for the quarter ended March 31 increased 31% to $4.57 million from $3.48 million.
The Eden Prairie, Minn., nanotechnology company's shares traded after-hours at $33.50, after closing at $29.63.
-Nicholas Hatcher; 201-938-5400; AskNewswires@dowjones.com
> Dow Jones Newswires
05-02-07 1750ET
Copyright (c) 2007 Dow Jones & Company, Inc.
Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology
Collaboration to Focus on Predictive Biomarkers for both Drug
Toxicity and Cancer
BOTHELL, Wash.--(BUSINESS WIRE)--May 2, 2007--Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that it has extended its collaboration agreement with the Institute for Systems Biology (ISB). The goal of the collaboration is to use Lumera's ProteomicProcessor(TM) to identify biomarkers associated with drug toxicity and cancer.
As previously announced, ISB researchers have demonstrated a label-free assay to determine protein expression patterns using a panel of specific antibodies printed on Lumera's NanoCapture-Gold(TM) microarray and analyzed on the company's ProteomicProcessor (TM) instrument system.
"We are quite pleased with the progress of the past year," said Dr. Leroy Hood, President of the Institute for Systems Biology. "Lumera's platform provides unique advantages in biomarker discovery and we are committed to moving the science forward."
"Early results from ISB have been proof positive that our technology adds significant value to the biomarker discovery market. We feel that with a continued emphasis on this project, we will arrive at a very important publication and will establish methods by which others will be able to develop their own assays," said Dr. Timothy Londergan, Lumera's Bioscience Business Unit.
As previously discussed by the company, biomarkers are important indicators of disease and their identification can lead to the development of targeted drug solutions to prevent or arrest the disease. Biomarker screening has been an increasing area of research growing from $5.4 billion in 2005 to an estimated $21 billion by 2012 according to Business Insights, a market research firm.
About Lumera
Lumera is an emerging leader in the field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for a broad range of bioscience, electro-optic, and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com/.
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including in its registrations statement on Form S-1, dated July 22, 2004 and its Quarterly Reports on Form 10-Q.
CONTACT: The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
801-244-9600 cell
SOURCE: Lumera Corporation
Alert Triggered for MFIC Corp.
MFIC's Trading Volume Exceeded Daily Average by 210.7%
MFIC is up $0.13 or 7.83% to $1.79 on heavy volume that exceeded its daily average by 210.7%. This performance is better than the broader averages as the S&P 500 is up 0.79% on the day.
Please note you will receive only one "Trading Volume Exceeds Daily Average" alert per day for MFIC Corp.
I read on Yahoo MB that someone sold a block of 20,000 shares and got 5.50 which is what can happen sometimes with thinly traded stocks with tiny market caps.
What caused the peculiar action of CVV on the market today?
CVV Form 8-K filed:
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=4888921
Note that FirstNano [recently acquired by CVV] did the research with the university and that the equipment was made by CVV! A double whammy fot CVV. Looks like a great combination.
That sounds like a rather important development.
CVV/First Nano Division mentioned:
University of Cincinnati Shatter World Records with Length of Carbon Nanotube Arrays
4/30/2007 12:49:54 AM
UC engineering researchers have developed a novel composite catalyst and optimal synthesis conditions for oriented growth of multi-wall CNT arrays. And right now they lead the world in synthesis of extremely long aligned carbon nanotube arrays.
Carbon nanotubes (CNTs) are of great interest because of their outstanding mechanical, electrical and optical properties. Intense research has been undertaken to synthesize long aligned CNTs because of their potential applications in nanomedicine, aerospace, electronics and many other areas.
Especially important is that long CNT arrays can be spun into fibers that are — in theory — significantly stronger and lighter than any existing fibers and are electrically conductive. Nanotube fibers are expected to engender revolutionary advances in the development of lightweight, high-strength materials and could potentially replace copper wire.
Years of effort by UC researchers Vesselin Shanov and Mark Schulz, co-directors of the University of Cincinnati Smart Materials Nanotechnology Laboratory, along with Yun YeoHeung and students, led to the invention of the method for growing long nanotube arrays. Employing this invention, the UC researchers (in conjunction with First Nano, a division of CVD Equipment Corporation of Ronkonkoma, New York) have produced extremely long CNT arrays (18 mm) on their EasyTube System using a Chemical Vapor Deposition (CVD) process.
Moreover, in a re-growth experiment on a separate substrate, they produced an 11-mm long CNT array. This array was then successfully peeled completely off the substrate. Without additional processing, the same substrate was reused for a successive growth that yielded an 8-mm-long CNT array.
Shanov notes that their research has had four major milestones this year already.
“First, we were able to grow the arrays up to 18 mm,” he says, ticking off the achievements. “Second, we produced a uniform carpet of 12-mm carbon nanotube arrays on a 4-inch wafer, which moves the invention into the field of scaled-up manufacturing for industrial application. Third, we filed a patent application on the inventions at the US Patent and Trademark Office and, fourth, we were invited to participate in a very prestigious workshop (invitation-only) organized by NASA and Rice University, where we presented our latest results. The workshop focused on “Single Wall Carbon Nanotube Nucleation and Growth Mechanisms.” This event was attended by the best scientists in the world working on synthesis carbon nanotubes, from Japan, China, Europe and the United States. Our presentation was accepted very well and confirmed that with the current record of 18-mm-long carbon nanotube arrays, and also with the big area growth on 4-inch wafers, we are leading in manufacturing extremely long CNT arrays.”
The Fine Print and Nano Details
The UC substrate for growing CNT arrays is a multilayered structure with a sophisticated design in which a composite catalyst is formed on top of an oxidized silicon wafer. Its manufacturing requires a “clean room” environment and thin-film deposition techniques that can be scaled up to produce commercial quantities. CNT synthesis is carried out in a hydrogen/hydrocarbon/water/argon environment at 750 degrees Celsius. The achievement of growing centimeter-long nanotube arrays provides hope that continuous growth of CNTs in the meter length range is possible. Leonard Rosenbaum, president and CEO of CVD Equipment Corporation, is looking forward to continuing the partnership with UC to bring this technology from the laboratory into full-scale production. UC is also partnering with another company to develop production of long CNT arrays that can be spun into fibers.
This research was supported by National Science Foundation (NSF) grant CMS-051-0823 (program directors Shih-Chi Liu & K. Jimmy Hsia) and the Office of Naval Research (program director Ignacio Perez) through North Carolina A&T SU (program directors Jag Sankar & Sergey Yarmolenko). CVD Equipment Corporation engineers developed and built the EasyTube System used by First Nano to grow the long CNT arrays.
http://altmine.mie.uc.edu/mschulz/public_html/smartlab/smartlab.html
Nanotech Casts a Tiny Net
By Jack Uldrich
The Motley Fool
April 30, 2007
Wondering where nanotechnology is headed next? Check out this month's Scientific American for the lowdown on carbon nanonets.
Instead of laying down exquisitely detailed paths of carbon nanotubes to make functional products, researchers have discovered that random networks of the super small, super-strong, highly conductive materials might be just as useful. These nanonets might usher in an era of inexpensive, highly functional "printable" electronics, light-emitting diodes, and flexible solar cells.
Why do the nets work as well as their more precise brethren? The article compares a random network of carbon nanotubes to an interstate highway system. Interconnected highways offer drivers many alternative paths to the same destination, and nanonets seem to do likewise for electrons.
This discovery's import for investors still isn't entirely clear. The Scientific American article was written by George Gruner; among many other things, he's the chief technology officer at Nanomix, a small, private nanotechnology company exploring ways to employ carbon nanonets in chemical and biological sensors. Nanomix happens to be a core holding of Motley Fool Rule Breakers recommendation Harris & Harris (Nasdaq: TINY), making an investment in Harris & Harris one way to play this opportunity.
The article also mentioned other companies working to apply carbon nanotubes to their products, include Carbon Nanotechnologies (which was recently acquired by Arrowhead Research (Nasdaq: ARWR)), DuPont (NYSE: DD), IBM (NYSE: IBM), Intel (Nasdaq: INTC), and Motorola (NYSE: MOT). If investors want to land nanotech's next big fish, they might want to focus on firms like these, which aim to use nanotech to create a cheaper, stronger net.
InPlay 8:51AM - Lumera and MUSC to develop antibody array for protein expression profiling (LMRA) 4.64 : Co announces that it has extended its collaboration agreement with the Medical University of South Carolina. In partnership with Lumera scientists, M.U.S.C researchers intend to develop an antibody array that will measure the levels and modifications of patient mitochondrial proteins. Under the agreement, Lumera will retain rights to commercialize all jointly developed intellectual property.
Sono-Tek Corp. Presents at a Leading International Nanotechnology Food and Agriculture Conference
Thursday April 26, 3:48 pm ET
MILTON, N.Y., April 26 /PRNewswire-FirstCall/ -- Sono-Tek Corporation (OTC Bulletin Board: SOTK - News) announced today that Dr. Joseph Riemer, VP of Engineering of Sono-Tek Corp. presented on April 23, 2007, at the Campden & Corleywood Food Research Association (CCFRA, UK) "Nanotechnology Food and Agriculture" workshop, Sono-Tek's unique capabilities in ultrasonic spray coatings, used for direct food contact and packaging films applications.
The objective of CCFRA's workshops is to present available and developing technologies, demonstrations and discussions of food industry needs and technical options in the newly emerging field of nanotechnology.
Included in Dr. Riemer's presentation were examples of successfully demonstrated ultrasonic spraying applications such as nutriceutical coatings, baked goods coatings, uniform spraying of sterilants on aseptic packaging surfaces, and coating of nano clay particles onto biodegradable food packaging films.
The benefits of these applications for food manufacturers are:
-- Introducing new food products
-- Cost-of-Goods savings
-- Enhancing energy efficiency and environmental friendliness
The nanotechnology workshop was attended by representatives of Europe's leading food manufacturing companies, research institutes and universities as well as regulatory and trade associations representatives.
"We are pleased to be invited to present at this prestigious crossroads of business and technology," said Dr. Christopher L. Coccio, President & CEO of Sono-Tek Corp. "Our unique capabilities in ultrasonic atomization are now an enabler for the food industry to, benefit from the progress in the field of nano materials," Dr. Coccio added.
For further information, contact Dr. Christopher L. Coccio, at 845-795-2020, or visit our website at http://www.sono-tek.com
Sono-Tek Corporation is a leading developer and manufacturer of liquid spray products based on its proprietary ultrasonic nozzle technology. Founded in 1975, the Company's products have long been recognized for their performance, quality and reliability.
This press release contains forward looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions; political, regulatory, competitive and technological developments affecting the Company's operations or the demand for its products; timely development and market acceptance of new products; adequacy of financing; capacity additions and the ability to enforce patents. We refer you to documents that the company files with the Securities and Exchange Commission, which includes Form 10-KSB and Form 10-QSBs containing additional important information.
--------------------------------------------------------------------------------
Source: Sono-Tek Corporation
Another take on the same news:
http://www.physorg.com/news96733560.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |